<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753362</url>
  </required_header>
  <id_info>
    <org_study_id>1965</org_study_id>
    <nct_id>NCT01753362</nct_id>
  </id_info>
  <brief_title>Liraglutide In Overweight Patients With Type 1 Diabetes</brief_title>
  <official_title>LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of liraglutide (a drug used to treat type
      2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to
      insulin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary endpoint of the study is to detect a difference in HbA1c after 26 weeks of treatment with Liraglutide or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference from baseline in mean weekly glucose concentrations</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous daily injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous daily injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as insulin
        pump) or multiple (four or more) injections of insulin per day. 2) Using a continuous
        glucose monitoring device (CGM) or regularly measuring their blood sugars four times daily.
        3) HbA1c of less than 8.5%. 4) Well versed with carbohydrate counting. 5) Age 18-75 years
        6) BMIâ‰¥ 25kg/m2 7) Age at diagnosis of type 1 diabetes should be &lt;30 years. 8) evidence of
        auto-immunity to beta cells (GAD-65 and islet cell antibody screen)

        Exclusion Criteria:

        1)Type 1 diabetes for less than 6 months; 2)Coronary event or procedure (myocardial
        infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in
        the previous four weeks; 3)Hepatic disease (transaminase &gt; 3 times normal) or cirrhosis;
        4)Renal impairment (serum eGFR &lt;30ml/min/1.73m2); 5)HIV or Hepatitis B or C positive
        status; 6)Participation in any other concurrent clinical trial; 7)Any other
        life-threatening, non-cardiac disease; 8)Use of an investigational agent or therapeutic
        regimen within 30 days of study. 9) history of pancreatitis 10) pregnancy 11) inability to
        give informed consent 12) history of gastroparesis 13)history of medullary thyroid
        carcinoma or MEN 2 syndrome. 14) Smokers will be advised not to change their amount of
        smoking for the duration of the study; 15) Use of any agent other than insulin for
        treatment of diabetes (metformin, pramlintide or thiazolidinediones.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY UB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paresh Dandona, MD</last_name>
    <phone>716-898-1940</phone>
    <email>pdandona@kaleidahealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>diabetes endocrinology center of WNY</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Dandona, MD</last_name>
      <phone>716-898-1940</phone>
      <email>pdandona@kaleidahealth.org</email>
    </contact>
    <investigator>
      <last_name>Paresh Dandona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Endocrinology Research Center of WNY</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Dandona, MD</last_name>
      <phone>716-898-1940</phone>
      <email>pdandona@kaleidahealth.org</email>
    </contact>
    <investigator>
      <last_name>paresh dandona, mbbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

